Alfons H H Bongaerts Selected Research

Bevacizumab (Avastin)

1/2015	89Zr-bevacizumab PET visualizes heterogeneous tracer accumulation in tumor lesions of renal cell carcinoma patients and differential effects of antiangiogenic treatment.
7/2014	Everolimus Reduces (89)Zr-Bevacizumab Tumor Uptake in Patients with Neuroendocrine Tumors.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Alfons H H Bongaerts Research Topics

Disease

4	Neoplasms (Cancer) 01/2018 - 07/2014
3	Breast Neoplasms (Breast Cancer) 01/2018 - 08/2014
1	Hemorrhage 01/2016
1	von Hippel-Lindau Disease (von Hippel Lindau Disease) 01/2016
1	Inflammation (Inflammations) 01/2016
1	Fecal Incontinence 01/2016
1	Fibrosis (Cirrhosis) 01/2016
1	Pain (Aches) 01/2016
1	Pneumonia (Pneumonitis) 01/2016
1	Prostatic Neoplasms (Prostate Cancer) 01/2016
1	Testicular Neoplasms (Testicular Cancer) 01/2016
1	Disease Progression 01/2015
1	Renal Cell Carcinoma (Grawitz Tumor) 01/2015
1	Neuroendocrine Tumors (Neuroendocrine Tumor) 07/2014

Drug/Important Bio-Agent (IBA)

4	89Zr-bevacizumabIBA 01/2016 - 07/2014
3	Estrogen ReceptorsIBA 01/2018 - 08/2014
2	Pharmaceutical PreparationsIBA 12/2017 - 01/2015
2	Vascular Endothelial Growth Factor A (Vascular Endothelial Growth Factor)IBA 01/2015 - 07/2014
2	Bevacizumab (Avastin)FDA Link 01/2015 - 07/2014
1	16-fluoroestradiolIBA 01/2018
1	AndrogensIBA 12/2017
1	Androgen Receptors (Androgen Receptor)IBA 12/2017
1	human ERBB2 proteinIBA 12/2017
1	Growth Differentiation Factor 15IBA 01/2016
1	V 70 (V70)IBA 01/2016
1	AnticoagulantsIBA 01/2016
1	Bleomycin (Blenoxane)FDA LinkGeneric 01/2016
1	C-Reactive ProteinIBA 01/2016
1	Cisplatin (Platino)FDA LinkGeneric 01/2016
1	Etoposide (VP 16)FDA LinkGeneric 01/2016
1	Transforming Growth Factors (Transforming Growth Factor)IBA 01/2016
1	Sunitinib (Sutent)FDA Link 01/2015
1	InterferonsIBA 01/2015
1	Biomarkers (Surrogate Marker)IBA 01/2015
1	5- (2,4- dihydroxy- 5- isopropylphenyl)- 4- (4- morpholin- 4- ylmethylphenyl)isoxazole- 3- carboxylic acid ethylamideIBA 08/2014
1	zirconium-89-trastuzumabIBA 08/2014
1	Proteins (Proteins, Gene)FDA Link 08/2014
1	Everolimus FDA Link 07/2014

Therapy/Procedure

1	Aftercare (After-Treatment) 01/2016
1	Drug Therapy (Chemotherapy) 01/2016
1	Radiotherapy 01/2016